The forecasted import value of Erythromycin to Brazil exhibits a declining trend from 2024 to 2028, decreasing from 3.2163 million USD in 2024 to 2.6252 million USD in 2028. The year-on-year percentage variation indicates a consistent decline, reflecting a decreasing demand or an increase in domestic production capabilities. The compound annual growth rate (CAGR) from 2024 to 2028 further underscores a downward trend, averaging a decrease in import value each year.

Future trends to watch for include:

The impact of government initiatives to bolster local manufacturing of pharmaceuticals, which could further reduce import reliance.
Changes in international trade policies or tariffs that might affect import costs.
Shifts in global supply chain dynamics, potentially influencing market prices and availability.
Consumer demand changes based on healthcare needs and new medical research findings.